Trial | NCT03589781  Report issue

Official Title

Investigating the Effects of Mikei® Red Reishi Essence EX on the Immune System of Prostate Cancer Patients and Patients With Non-cancerous Conditions of the Prostate

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Withdrawn

  • Study Participants

    0
The primary objective of this study is to determine the effects of Mikei® Red Reishi Essence EX extract powder on the immune function of prostate cancer patients and patients with non-cancerous conditions of the prostate.
The purpose of this study is to determine the effects of Mikei® Red Reishi Essence EX, a natural supplementary dietary product, on the immune function of prostate cancer patients and patients with non-cancerous conditions of the prostate. According to limited published scientific research and clinical studies, Reishi mushroom extract may support the body's immune function. According to cancer immunology research, at early stage of tumor development, the immune system can mount defensive actions to eliminate or inhibit tumor growth. This study is to examine the specific effect of Mikei® Red Reishi Essence EX on the immune function of prostate cancer patients and patients with non-cancerous conditions of the prostate.
Study Started
Nov 05
2020
Anticipated
Primary Completion
Mar 01
2021
Study Completion
Mar 01
2021
Last Update
Mar 30
2021

Dietary Supplement Mikei Red Reishi Essence EX

Dosage is 490 mg per capsule, 3 capsules twice a day with food or water. Total of 6 capsules per day.

  • Other names: Ganoderma lucidum (fruiting body) extract, lingzhi

Dietary Supplement Placebo

Matching placebo. Consume 3 capsules twice a day with food or water. Total of 6 capsules per day.

Mikei Red Reishi Essence EX Experimental

There are two groups (50 participants total) in this clinical study, one group (35 participants) will be given Mikei® Red Reishi Essence EX product (Product Group).

Placebo Placebo Comparator

Another group (15 participants) will be given the placebo (Placebo Group). Placebo is a pill that looks like a drug but has no drug or other active ingredients.

Criteria 

Inclusion Criteria:

Male age between 50-85
Diagnosed with prostate cancer or high-grade PIN within the last 24 months through the most recent biopsy; or patients who have a total PSA level above 4.0 but have not been diagnosed with prostate cancer yet
Has not received any prostate cancer therapy including surgery, chemotherapy, hormone therapy, or radiation therapy
Clinical Gleason score of the tumor is ≤6 for patients ≤70 years or ≤7 for >70 years; (non-applicable for non-cancer patients with elevated PSA or high-grade PIN)
The clinical stage of the cancer is T1c or below (non-applicable for non-cancer patients with elevated PSA or high-grade PIN)
The patients have been recommended for and placed under active surveillance without immediate treatment
Able to provide written informed consent

Exclusion Criteria:

Patients taking mushroom (including reishi) or other herbal products/natural supplements
Patients with a known allergy to mushrooms
Prisoners
Patients who receive treatment with 5-alpha reductase inhibitors (finasteride [Propecia®, Proscar®,], or dutasteride [Avodart®) within 28 days prior to randomization are not eligible. The use of these drugs is not allowed during the patients' study participation.
Patients with a history of non-cutaneous malignancy in the previous 5 years are not eligible.
Patients taking warfarin, heparin, Aspirin >81mg/day, or other prescribed blood thinners: Reishi may increase the risk of bleeding.
Patients with platelets levels below 139 X 103/ul or history of bleeding disorders
Patients undergoing chemotherapy: Reishi may make some chemotherapy drugs less effective.
Patients with any known immune disorder, including but not limited to HIV or other primary or secondary immune deficiency diseases, autoimmune diseases, history of or being considered for organ transplants, etc.
Patients taking immunosuppressants (Corticosteroids, Calcineurin inhibitors, mTOR inhibitors, IMDH inhibitors, Biologics, Monoclonal antibodies): Reishi can stimulate immune responses.
Patients taking cytochrome P450 2E1, 1A2, and 3A sensitive substrate drugs: Reishi may increase the risk of side effects of these drugs.
Patient has total bilirubin >1.5 MG/DL, alanine aminotransferase (ALT) >51 U/L or aspartate aminotransferase (AST) >46 U/L.
No Results Posted